AAN –Toronto, April 11, 2010 Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort INTRODUCTION.

Slides:

Advertisements

Similar presentations

Agenda: - Certification Platform: performance for training - I round - II round -Feedback from naives - Beta testers proposals - Congress presentations.

Advertisements

Agenda: - Update master tracers - Update validation vs pathology - Hippocampal 3D Object for AR Visualization - Papers - Next congress presentations &

Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort 4 th Meeting, Paris, July 20, 2011 Principal Investigators: Giovanni.

Agenda: - Validation vs Pathology - Congress presentations & Meetings - Paper publication VI PMT meeting – Feb 1, 2011.

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

Answers to previous TC issues: - Demographic features of the selected subjects (age, sex, disease, ApoE) - Check for SIEMENS-Allegra scans at 3T for the.

ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh.

AAN –Toronto, April 11, 2010 Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort INTRODUCTION.

Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort 3 rd Meeting, Honolulu, April 13, 2011 Principal Investigators:

Agenda: - Update on master tracers’ segmentation check - Update validation vs pathology - PMT application submission of “Study on the validation of VSRAD”

Agenda: - New benchmark ICC and Dice’s - Training set for Naïve - Beta testers proposals - Congress presentations XII PMT meeting – September 26, 2012.

Agenda: - Axes check - Validation vs Pathology - Paper Publications - Congress presentations & Meetings VII PMT meeting – Feb 29, 2012.

Agenda: - Validation Harmonized Protocol: update - Validation vs pathology - Hippocampal Label Expansion project: update - News - Congress presentations.

Agenda: - Certification Platform: Training - I round - Beta testers proposals - Congress presentations - Paper “check for axes” XIII PMT meeting – October.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

BERG SYMPOSIUM WASHINGTON UNIVERSITY SEPT 2003 MICHAEL W WEINER MD.

Public Health Julie C. Chapman, PsyD Director of Neuroscience War Related Illness & Injury Study Center Veterans Affairs Medical Center, Washington, DC.

Li Wang1, Feng Shi1, Gang Li1, Weili Lin1, John H

Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.

Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort 1 th Project Management Team Meeting August 31, 2011.

Cognitive and Brain Aging in the Baltimore Longitudinal Study of Aging Susan M. Resnick, Ph.D. Laboratory of Personality and Cognition National Institute.

CLINICAL & TRANSLATIONAL SCIENCE AWARDS CLINICAL & TRANSLATIONAL SCIENCE AWARDS Transforming Biomedical Research To Improve the Health of Our Nation’s.

TEMPLATE DESIGN © All PET scans were processed to uniform resolution as implemented by ADNI (Joshi, 2009) to minimize.

Risk of Developing Alzheimer’s Disease in Persons with MCI

Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects Liana G. Apostolova, Amity E. Green, Kristy S. Hwang, Jonathan.

Evaluation of Multi-Center Diffusion Tensor Imaging VA Magnotta 1, GS Bonett 1, J Turner 6, B Mueller 2, A Juhl 1, K Lim 2, S Reading 3, E Aylward 5, M.

Quantitative analysis of radiologic images: Image segmentation and registration, statistical atlases Christos Davatzikos, Ph.D. Professor of Radiology.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.

Agenda: - Axes check - Validation vs Pathology - Publication Policy - Paper Publications - Congress presentations & Meetings VIII PMT meeting – Mar 21,

Dr Hussein Farghaly PSMMC

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part C – AD brain scans - anatomical NUCLEAR MEDICINE GRAND.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.

AAN –Toronto, April 11, 2010 Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort METHODS.

Automatic pipeline for quantitative brain tissue segmentation and parcellation: Experience with a large longitudinal schizophrenia MRI study 1,2 G Gerig,

References [1] Coupé et al., An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. IEEE TMI, 27(4):425–441, 2008.

Functional MRI: Physiology and Methodology

Structural MRI as a Biomarker of Disease Progression in AD Department of Diagnostic Radiology and MRI Research Lab Presented by Clifford Jack, M.D. at.

Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.

Developing outcome prediction models for acute intracerebral hemorrhage patients: evaluation of a Support Vector Machine based method A. Jakab 1, L. Lánczi.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Laboratory of Neuro Imaging: Graduate Students Sarah K. Madsen Mentor: Paul M. Thompson, Ph.D. Committee: Susan Y. Bookheimer, Ph.D., Jamie D. Feusner,

MR SPECTROCOPY AND MRI TO MEASURE TREATMENT OF NEURODEGENERATION MICHAEL W. WEINER Professor of Radiology, Medicine, Psychiatry, and Neurology, U.C.S.F.

Advanced brain imaging and neurodegenerative disorders. Dott.ssa Ingrid Inches.

Sint Lucas-Andreas Hospital, Amsterdam

CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS

Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of Short- term conversion to AD: Results from ADNI Xuejiao.

DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

EUROPEAN ADNI/PharmaCOG

Rosa Maria Moresco University of Milan Bicocca

MORPHOMETRIC brain volume measurements in medical cadaveric scans WITH DEMENTIA and metabolic syndrome Natasa Dragicevic* MD PhD, Joe Grajo*

Variation in health state preferences across local and international populations: East doesn’t meet West CADTH symposium Panel Session April 12, 2016.

What is Psychology?.

conflicts of interest to report.

ADI Disease International 7-10 March, 2012

Detecting Gray Matter Maturation via Tensor-based Surface Morphometry

Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health

Clifford R. Jack, Josephine Barnes, Matt A. Bernstein, Bret J

Clifford R. Jack, Josephine Barnes, Matt A. Bernstein, Bret J

Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.

Neuroimaging and macroscopic features.

Serial imaging of a child with a clinical complex of bilateral facial PWS, early-onset severe seizures, and fatally progressive encephalopathy. Serial.

Figure 2 Neuroimaging characteristics of TARDBP carriers

Amygdalar local structural differences in early- and late-onset Alzheimer's patients Enrica Cavedo, Michela Pievani, Marina Boccardi, Samantha Galluzzi,

Examples of the visual rating scale for the medial and lateral temporal lobe on MR coronal images displayed conventionally with the letter on the right.

Defining diagnostic brain MRI markers in early MSA

Presentation transcript:

AAN –Toronto, April 11, 2010 Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort INTRODUCTION

Structure: MR hippo volumetry Biochemistry: CSF tau/Abeta Function: FDG PET Amyloid deposits: PET BACKGROUND Hippocampal volume as a diagnostic marker Dubois, Feldman et al., Lancet Neurol 2007

Geuze et al., Mol Psychiatry 2005;10: Ref.Med border Lat border Inf border Norm. hippo vol (cm 3 ) LeftRight Watson et al. Mesial edge of temporal lobe Temp horn of lat ventr Incl subicular complex & uncal cleft w/ border separating subicular complex from parahippo gyrus Zipursky et al. Regional outline at choroidal fissure Not mentioned The interface of hippocampal tissue and parahippocampal gyrus white matter BACKGROUND The effect of segmentation protocols on hippocampal volume

BACKGROUND Hippocampal volume as an outcome measure in trials of disease modifiers DrugStudyEffectSegment. methodRef TramiprosateAlphase 68% (100 mg) 120% (150 mg) n.m.Gauthier et al., JNHA 2009 AtorvastatinADCLT “Chv* mm³ -134±174 vs - 583±354 p>.05” Manual protocol Insausti et al., 1998 AJNR; Machulda et al., 2001, Neuroimage Sparks et.a,l CCJM,2008 LEADe “significant at p<.05” MIDAS (semiautomated) Jones et al., Alz&Dem 2008 Feldman et al., Neurology 2010 AN1792 “Chv* % 3.78±2.63 vs 2.86±3.19 p = 0.124” Manual protocol Watson et al., 1992, Neurology Fox N et al., Neurology, 2005 Xaliproden Sanofi- Aventis Trials “significant atrophy” §n.m.From Vellas B et al. (Review), Lancet Neurol.,2008 Donepezil “p= 0.07” ε4 carriers only Manual protocol Jack et al., 1989;Radiology Jack et al., 2004; Neurology Jack CR et al., Neurobiol. Aging, 2008 * Chv= Change in hippocampal volume; § referenced link not working; n.m. = not mentioned

BACKGROUND Hippocampal volume (manual segmentation) as gold standard for automated segmentation algorithms Morey et al., NeuroImage 2009

To Harmonize Available Protocols for Manual Hippocampal Segmentation To Test the Validity of the Harmonized Protocol AIMS

F Barkhof/P ScheltensAmsterdam B Dubois/S LehericiParis N FoxLondon GB Frisoni Brescia H Hampel/J PantelFrankfurt A SimmonsLondon H SoininenKuopio S TeipelRostock LO WahlundStockholm THE WORKGROUP EADC

CR Jack Jr Rochester, MN G Barzokis UCLA, CA D Bennet Chicago, IL J Csernansky NorthW U, WA C DeCarli UC Davis, CA M De Leon New York, NY J Kaye Portland, OR R Killiany Boston USM, MA PM Thompson LoNI, UCLA, CA M Weiner/S Mueller UCSF/VAMC THE WORKGROUP ADNI

THE WORKGROUP other relevant hippo experts R CamicioliUniv Alberta, Canada J O’BrienNewCastle, UK J PruessnerMcGill, QC, Canada

EADC-ADNI P.I.s B VellasToulouse, France B WinbladStockholm, Sweden M WeinerUCSF, US Population-based studies M Breteler/ T Den HeijerRotterdam Scan Study P Sachdev/ JJ Maller PATH through life L LaunerNIA Bethesda W JagustBerkeley THE WORKGROUP Advisory Boards

Statistical Board S DuchesneLaval Univ, Canada L CollinsMNI, McGill, Montreal P PasqualettiAFaR, Rome Clinical Advisor PJ VisserMaastricht, The Netherlands Dissemination/Education G WaldemarCopenhagen, Denmark THE WORKGROUP Boards

Marina Boccardi psychologist, PhD Rossana Ganzola psychologist Enrica Cavedopsychologist Michela Pievanimathematician Anna Carolimathematician Alberto Redolfibioinformaticist THE WORKGROUP Personnel in Brescia